Klein Matthew B.

Klein (CEO) sells 12,572 shares for $917,153.54 via 4 transactions; pre-arranged 10b5-1 plan.

Klein, as CEO of PTCT, executed 4 separate sales totaling 12,572 shares for $917,153.54 on 2026-05-13 and 2026-05-14, reducing his holdings from 406,570 shares to 393,998 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. At the current price of $71.47, the stock is -18.3% from its 52-week high of $87.50 and has declined -2.8% over the past 30 days. The company reported revenue of $272,551,000.00 in its latest quarter with net income of -$2,809,000.00 and annual revenue growth of +114.5%, offsetting concerns about current profitability. The scheduled nature of these sales limits inference about Klein's current sentiment; investors should note the filing occurs as a matter of plan mechanics rather than active market timing decision.

CEO Matthew Klein sold 7,371 PTCT shares at $69.36 on 2026-02-18 ($511.3K); stock down -18.1% from 52-week high.

Klein's sale of 7,371 shares represents a 1.9% reduction in his holdings, leaving him with 387,082 shares post-transaction. The stock has declined significantly since the sale date: -6.5% over 30 days and -10.0% over 90 days from the transaction price of $69.36, currently trading at $70.66. Examining his prior trades at PTCT specifically, three recent sales (Jan 7, Jan 6, Dec 30) showed negative 30-day returns (-3.6%, -6.0%, -0.3%), and his one measurable 90-day outcome at this ticker was +31.3%, indicating no pattern of well-timed selling at PTCT's 90-day mark (0 of 1 prior sells were well-timed). The company maintains a low P/E of 3.25 on strong fundamentals (annual revenue growth of +114.5%, net income $15.9M, and market cap $5.8B), which provides context for evaluating whether the sale reflects operational concerns or routine portfolio activity. The lack of measurable 90-day outcomes for three of his four same-ticker sales limits the ability to assess whether this sale follows an established pattern of timing discipline at this specific security.

PTCT CEO Klein sold 8,165 shares for $629,895.23 in 2 transactions (Jan 6-7); stock up 4.6% (30d), -10.9% from 52-week high.

Matthew B. Klein, CEO, sold 8.2K shares in 2 separate open-market transactions totaling $629,895.23 at blended average price $77.15, leaving him with 397.0K shares post-transaction. The sales occurred at prices ($76.95 on 2026-01-06 and $77.48 on 2026-01-07) near the current market price of $76.85, representing -10.9% from the 52-week high of $86.25. Klein's cross-ticker track record shows poor sell timing (90-day well-timed rate 0.00%), with his prior 2 sells followed by average 90-day returns of +31.3%, indicating he sold before subsequent stock appreciation. At PTCT specifically, his prior sell on 2025-08-05 was similarly poorly timed, with a +31.3% 90-day return afterward. The company is unprofitable on a full-year basis, with declining annual revenue growth (-14.0%), though recent quarter net income was positive at $15.9M on $211.0M revenue, and the stock has gained 4.6% and 16.0% over the last 30 and 90 days respectively.

CEO Matthew B. Klein sells 8,089 shares of PTCT at $76.64; retains 341,875 shares post-transaction.

Matthew B. Klein, PTCT's Chief Executive Officer, sold 8,089 shares at $76.64 on 2025-12-30, representing a 2.3% reduction of his pre-transaction holdings. The sale occurred with the stock trading 11.0% below its 52-week high of $86.25, and 30-day and 90-day price momentum have been modestly positive (1.3% and 17.4% respectively). His prior sale of PTCT shares on 2025-08-05 generated a 90-day return of 31.3%, indicating that after his previous similar sale the stock rose materially — a poorly-timed exit relative to subsequent price action. The company's fundamentals present a mixed picture: near-term profitability ($15.9M net income in the latest quarter) contrasts with negative full-year results and revenue decline of 14.0% year-over-year, coupled with a low P/E of 8.20 that may reflect underlying earnings pressure.

CEO Klein Matthew B. sold 10,739 shares of PTCT at $51.74, reducing holdings by 3.1% to 337.8K shares.

Klein Matthew B., Chief Executive Officer, sold 10,739 shares at $51.74 for total value of $555,635.86, reducing his holdings from 348.5K shares to 337.8K shares. The sale occurred at a price -10.6% from the 52-week high of $57.17, and the stock has appreciated 4.2% over the past 30 days and 25.4% over 90 days. Notably, PTC Therapeutics' fundamentals show significant headwinds: annual revenue declined 14.0% year-over-year despite a strong latest-quarter revenue of $1.2B, the company posted negative full-year net income despite a $866.6M positive result in the latest quarter, and the stock trades at a P/E of 6.81 reflecting market concern about sustainability. The modest 3.1% reduction in CEO holdings warrants attention given the company's operational contraction and negative full-year profitability, signaling potential caution from the insider despite recent positive stock momentum.